The biotech mergers and acquisitions landscape is currently confronting various hurdles, including frozen capital markets, regulatory uncertainties at the U.S. Food and Drug Administration and U.S. Department of Health and Human Services, in addition to tariffs. Despite these challenges, there are actionable strategies that biotech boards and management teams can pursue to maximize value when considering spinoff opportunities.
In particular, spinoffs that might qualify as tax-free require significant advance planning and precise execution to be successful. Such diligence is crucial to navigate the intricate regulatory and transactional complexities involved.
For more detailed insights on strategizing spinoff transactions in the biotech sector, the original article is available on Law360.